Moneycontrol PRO
HomeNewsBusinessStocksCadila Healthcare share price hits 52-week high on USFDA nod for cancer drug

Cadila Healthcare share price hits 52-week high on USFDA nod for cancer drug

The drug will be manufactured at the group’s Ahmedabad SEZ facility.

April 09, 2020 / 12:03 IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Cadila Healthcare share price touched 52-week high of Rs 378, rising 8 percent intraday on April 9 after the company received final approval from the US drug regulator for a blood cancer drug.

Zydus Cadila has received final approval from the US Food and Drug Administration to market Imatinib Mesylate Tablets, 100 mg and 400 mg, as per a company release.

This medication is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumours of the stomach and digestive system.

The drug will be manufactured at the group’s Ahmedabad SEZ facility, it added.

At 1147 hours, Cadila Healthcare was quoting at Rs 355.70, up Rs 5.75, or 1.64 percent, on the BSE.

Moneycontrol News
first published: Apr 9, 2020 12:03 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347